<?xml version="1.0" encoding="UTF-8"?>
<p>ACE2 is the receptor for coronaviruses, including SARS-CoV-2 (
 <xref rid="B4" ref-type="bibr">4</xref>). As a result of SARS-CoV-2 binding to ACE2, the enzyme is no longer functional (
 <xref rid="B13" ref-type="bibr">13</xref>). Thus, the pro-inflammatory Ang II-AT
 <sub>1</sub>R is no longer blocked by the ACE2-Angâ€“(1-7)-MasR pathway and it is this imbalance that causes acute lung injury (
 <xref rid="B13" ref-type="bibr">13</xref>). A multi-centered double blind clinical trial has recently been established to test the efficacy of treating patients suffering from COVID-19 with an ARB (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04312009" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04312009</ext-link>). A second is investigating the outcomes of treatment of COVID-19 patients with ACEIs or ARBs (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04331574" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04331574</ext-link>).
</p>
